Unlock the Secrets to Longevity and Chronic Illness With 3rd Generation Oral Peptides

I keep coming back to one idea in this talk: the immune system is not a side character in aging and chronic illness—it is closer to the director. I lay out the teeter-totter first: the TH1 and regulatory side against the TH2 and TH17 side, and how the thymus winding down from childhood on quietly shifts that balance until an aged immune phenotype takes over. From there, the dominoes are familiar to anyone who works with complex patients: hypothalamic and pituitary hormone dysfunction, mitochondria slipping into the cell danger response, leaky gut, cognitive fog, and the low-grade inflammation that tracks with how old you actually are on the inside.

Then I spend real time on senescent cells, because that is where a lot of the longevity research has landed. These are worn-out cells that should be cleared and instead stick around, secreting the inflammatory signals that show up in the diseases we associate with aging, while falling natural killer function lets them pile up. I connect that to the chronically ill patient, who is often carrying a heavy senescent load from an unresolved infection or autoimmune process, and I make the case for immune-directed peptides and bioregulators, the third-generation oral tools I have been working with, as a way to work on that layer. It runs dense, and that is on purpose.

The more you know here, the more you know you do not know.

- - - - -

About the Host:

Dr. Kent Holtorf, MD, has spent most of his career on the patients other clinics send away: tick-borne illness, chronic fatigue syndrome, fibromyalgia, CIRS, mast cell activation, long COVID, and the multi-system cases that never fit one specialty. He is the medical director of Holtorf Medical Group, the founder and medical director of Integrative Peptides, and president and medical director of the National Academy of Hypothyroidism, a nonprofit built around the argument that thyroid diagnosis in the United States has not caught up with its own published literature.

He came to peptides as a patient first. Years of chronic Lyme, Babesia, and Bartonella that did not respond to high-dose IV antibiotics ended in heart failure from fibrosis, and it was a course of peptides that turned it around. He has since given close to a hundred CME-approved presentations worldwide, published in peer-reviewed journals, and written Mold Illness: The Peptide Protocol for the Rapid Treatment of CIRS.

- - - - -

Social Handles:

Websites: ⁠https://holtorfmed.com⁠; ⁠https://integrativepeptides.com⁠

Instagram: ⁠https://www.instagram.com/integrativepep⁠⁠ ; https://www.instagram.com/holtorfmedicalgroup⁠

- - - - -

PODCAST

Thank you for listening.

Please subscribe and share.

This podcast is produced by DrTalks.com

https://drtalks.com/podcast-service/